Like any 3D printing material, graphene isn’t perfect; it can be carcinogenic if the particles are inhaled, for example, and more research is needed into how to optimally 3D print it. The material is about to be the subject of a new research study conducted by the Herston Biofabrication Institute at the Queensland University of Technology. The researchers plan to investigate the use of graphene for biomedical treatments.
The graphene used in the study will be provided by Graphene Manufacturing Group, a Brisbane, Australia-based company that is currently one of the world’s leading manufacturers of graphene in bulk.
“We will be providing the Institute with a range of different graphene platelet sizes and shapes to assist with essential research into personalised vascular surgery prognosis, training, and treatment,” said Craig Nicol, Founder and Managing Director of Graphene Manufacturing Group. “GMG has expertise in dispersing graphene effectively into polymer and other materials and we will be advising and mentoring the process of adapting graphene dispersions for 3D printing.”
Graphene Manufacturing Groups’ goals include making graphene accessible for everyday products for applications that were previously not possible due to the high costs of manufacturing the material. The company’s proprietary process creates a continuous, bulk supply of graphene at a much lower cost that existing production methods.
The $54 million Herston Biofabrication Institute was recently established at Herston Health Precinct, which is adjacent to Royal Brisbane and Women’s Hospital. The Institute will be collaborating with Graphene Manufacturing Group as well as surgeons, academics and other industry partners to develop 3D platform technologies such as scanning, modeling and printing in three major areas of healthcare: personalized orthopedics, burn injury treatment and vascular surgery. The project is being co-led by Dr. Jenkins, head of surgical services at Metro North Health.
“Graphene is 200 times stronger than steel, 1,000 times more conductive than copper, heat resistant to 3,500 degrees Celsius and has implications for virtually every industry that comes to mind,” Nicol said. “Our technology allows us to produce high-quality graphene nano-platelets more affordably than any competitor globally, making it perfect for medical trials and health-based research such as the Herston Biofabrication Institute work. We expect to see our graphene lead to true health-based innovation delivering significant and long-lasting health benefits through the creation of stronger and more effective stents with potential antibacterial properties, cell culture biocompatibility and enhanced mechanics.”
The State Government is supporting the work of 30 researchers through $7.2 million worth of Advance Queensland Industry Research Fellowships.
Discuss this and other 3D printing topics at 3DPrintBoard.com or share your thoughts below.
You May Also Like
3D Printing News Briefs, August 25, 2021: Software Beta, Self-Replicating Printer, & More
We’re starting with materials in today’s 3D Printing News Briefs, as XJet as announced the commercial availability of alumina ceramic. Moving on, Raise3D has announced the ideaMaker 4.2.0 beta, and...
Facility for Mass Roll-to-Roll 3D Printing to Be Opened by MIT Spinout
Massachusetts manufacturing startup OPT Industries uses automation engineering, computational design, and materials science to develop and manufacture customizable functional materials for 3D printing. The MIT spinout company became well-known for its...
3D Printed Sensor Created by Fraunhofer and ARBURG
One of the many Holy Grails of 3D printing is the ability to 3D print fully functional items in a single build process. Companies like Inkbit and Sakuu are after...
Inkbit Raises $30M in Series B Funding, Plans to Expand Production of 3D Printing System
MIT spinout Inkbit has raised $30 million in a Series B funding round led by venture capital firm Phoenix Venture Partners (PVP). The company intends to use the funds to...
View our broad assortment of in house and third party products.